Paul Matteis
Stock Analyst at Stifel
(1.37)
# 3,344
Out of 4,843 analysts
113
Total ratings
38.36%
Success rate
-12.03%
Average return
Main Sectors:
Stocks Rated by Paul Matteis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $78 → $94 | $61.33 | +53.27% | 2 | May 29, 2025 | |
| VIGL Vigil Neuroscience | Downgrades: Hold | $11 → $8 | $7.89 | +1.39% | 2 | May 28, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $300 → $345 | $304.56 | +13.28% | 14 | Mar 31, 2025 | |
| NMRA Neumora Therapeutics | Downgrades: Hold | $6 → $2 | $0.72 | +179.21% | 2 | Mar 7, 2025 | |
| SION Sionna Therapeutics | Initiates: Buy | $32 | $13.86 | +130.88% | 1 | Mar 4, 2025 | |
| GHRS GH Research | Maintains: Buy | $18 → $32 | $12.04 | +165.78% | 2 | Feb 27, 2025 | |
| CMPS COMPASS Pathways | Initiates: Buy | $11 | $4.16 | +164.42% | 1 | Feb 27, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Hold | $490 → $494 | $442.05 | +11.75% | 18 | Dec 16, 2024 | |
| QURE uniQure | Maintains: Buy | $12 → $32 | $14.47 | +121.15% | 1 | Dec 16, 2024 | |
| SAGE Sage Therapeutics | Maintains: Hold | $10 → $6 | $6.46 | -7.12% | 5 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $4 | $1.33 | +200.75% | 4 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $2.58 | +287.60% | 3 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $44 → $60 | $17.01 | +252.73% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $25 → $36 | $30.61 | +17.61% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $115 → $87 | $58.07 | +49.82% | 8 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $41 → $66 | $11.96 | +451.84% | 3 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $8.18 | +327.87% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $50 → $53 | $33.51 | +58.16% | 5 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $26 → $21 | $21.57 | -2.64% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $3.67 | +691.27% | 1 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $141 → $144 | $123.02 | +17.05% | 8 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $287 | $129.79 | +121.13% | 6 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.72 | +635.29% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $2.58 | +365.12% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $24 | $1.46 | +1,543.84% | 2 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $36 → $5 | $0.31 | +1,500.00% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $32 | $11.80 | +171.19% | 1 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $1.03 | +2,534.15% | 1 | Jul 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $9.11 | +53.68% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $64 | $6.01 | +964.89% | 1 | Feb 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $340 | $21.75 | +1,463.22% | 1 | Dec 21, 2016 |
Rhythm Pharmaceuticals
May 29, 2025
Maintains: Buy
Price Target: $78 → $94
Current: $61.33
Upside: +53.27%
Vigil Neuroscience
May 28, 2025
Downgrades: Hold
Price Target: $11 → $8
Current: $7.89
Upside: +1.39%
Alnylam Pharmaceuticals
Mar 31, 2025
Maintains: Buy
Price Target: $300 → $345
Current: $304.56
Upside: +13.28%
Neumora Therapeutics
Mar 7, 2025
Downgrades: Hold
Price Target: $6 → $2
Current: $0.72
Upside: +179.21%
Sionna Therapeutics
Mar 4, 2025
Initiates: Buy
Price Target: $32
Current: $13.86
Upside: +130.88%
GH Research
Feb 27, 2025
Maintains: Buy
Price Target: $18 → $32
Current: $12.04
Upside: +165.78%
COMPASS Pathways
Feb 27, 2025
Initiates: Buy
Price Target: $11
Current: $4.16
Upside: +164.42%
Vertex Pharmaceuticals
Dec 16, 2024
Maintains: Hold
Price Target: $490 → $494
Current: $442.05
Upside: +11.75%
uniQure
Dec 16, 2024
Maintains: Buy
Price Target: $12 → $32
Current: $14.47
Upside: +121.15%
Sage Therapeutics
Dec 16, 2024
Maintains: Hold
Price Target: $10 → $6
Current: $6.46
Upside: -7.12%
Dec 16, 2024
Downgrades: Hold
Price Target: $4
Current: $1.33
Upside: +200.75%
Nov 13, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $2.58
Upside: +287.60%
Nov 12, 2024
Maintains: Buy
Price Target: $44 → $60
Current: $17.01
Upside: +252.73%
Nov 5, 2024
Upgrades: Buy
Price Target: $25 → $36
Current: $30.61
Upside: +17.61%
Sep 17, 2024
Maintains: Buy
Price Target: $115 → $87
Current: $58.07
Upside: +49.82%
Aug 16, 2024
Maintains: Buy
Price Target: $41 → $66
Current: $11.96
Upside: +451.84%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $8.18
Upside: +327.87%
Jun 27, 2024
Maintains: Hold
Price Target: $50 → $53
Current: $33.51
Upside: +58.16%
May 9, 2024
Maintains: Hold
Price Target: $26 → $21
Current: $21.57
Upside: -2.64%
Apr 30, 2024
Initiates: Buy
Price Target: $29
Current: $3.67
Upside: +691.27%
Dec 18, 2023
Maintains: Buy
Price Target: $141 → $144
Current: $123.02
Upside: +17.05%
Dec 14, 2023
Maintains: Buy
Price Target: $315 → $287
Current: $129.79
Upside: +121.13%
Nov 28, 2023
Initiates: Buy
Price Target: $20
Current: $2.72
Upside: +635.29%
Nov 14, 2023
Initiates: Buy
Price Target: $12
Current: $2.58
Upside: +365.12%
Jun 14, 2023
Reiterates: Buy
Price Target: $24
Current: $1.46
Upside: +1,543.84%
Jun 23, 2022
Downgrades: Hold
Price Target: $36 → $5
Current: $0.31
Upside: +1,500.00%
Jun 8, 2022
Maintains: Buy
Price Target: $54 → $32
Current: $11.80
Upside: +171.19%
Jul 26, 2021
Initiates: Buy
Price Target: $27
Current: $1.03
Upside: +2,534.15%
Mar 12, 2020
Initiates: Buy
Price Target: $14
Current: $9.11
Upside: +53.68%
Feb 21, 2018
Maintains: Outperform
Price Target: $53 → $64
Current: $6.01
Upside: +964.89%
Dec 21, 2016
Initiates: Outperform
Price Target: $340
Current: $21.75
Upside: +1,463.22%